NEW YORK, April 4 /PRNewswire/ -- On March 26, Joseph Cummins, Chief Executive Officer for Amarillo Biosciences, Inc. updated the investment community in an exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on “Interviews.” The interview can be accessed either by locating the company’s ticker symbol under the appropriate exchange on the left-hand column of the “Interviews” section of the site, or by entering the company’s ticker symbol in the Search Archive window.
About Amarillo Biosciences:
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren’s syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/ .
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two hundred eighty dollars from Amarillo Biosciences, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )
Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comWallStreet Direct, Inc.
CONTACT: Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST
